The Role of CXCL5 in Acute Coronary Syndrome and Statin Effects
Author Information
Author(s): Zineh Issam, Beitelshees Amber L., Welder Gregory J., Hou Wei, Chegini Nasser, Wu Jun, Cresci Sharon, Province Michael A., Spertus John A.
Primary Institution: University of Florida College of Pharmacy
Hypothesis
Variation in the chemokine gene CXCL5 is associated with ACS prognosis and statin use modifies this association.
Conclusion
CXCL5 genotype is linked to increased mortality in ACS patients, and statin therapy significantly reduces mortality in certain genotypes.
Supporting Evidence
- C/C genotype was associated with a 2.7-fold increase in 3-year all-cause mortality compared to G/G+G/C.
- Statins significantly reduced mortality in G/G individuals only, with a 58% relative risk reduction.
- Atorvastatin dose-dependently decreased IL-1β-stimulated ENA-78 concentrations.
Takeaway
This study found that a specific gene variant can increase the risk of dying from heart problems, but taking certain medications called statins can help some patients live longer.
Methodology
The study used a prospective cohort of ACS patients to analyze the association of the CXCL5 −156 G>C polymorphism with 3-year all-cause mortality and the effect of statins on this association.
Potential Biases
Potential bias due to the observational nature of the study and lack of control over medication adherence.
Limitations
The study lacked data on white blood cell counts and specific statin types, and the small sample size for subgroup analyses may lead to false positives.
Participant Demographics
Mean age 61 years, 36% women, 79% Caucasian.
Statistical Information
P-Value
p=0.002
Confidence Interval
95%CI 1.19–5.87
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website